腹腔内化疗及其在伴腹膜转移胃癌治疗中不断演变的角色。
Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases.
机构信息
1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
出版信息
Chin J Cancer Res. 2014 Feb;26(1):1-3. doi: 10.3978/j.issn.1000-9604.2014.02.06.
Advanced gastric cancer (GC) has been recognized as lethal disease when peritoneal metastases (PM) occurred. There is no standard treatment for advanced GC with PM. Until 1980s, the therapeutic arena for these patients had remained stagnant, with no therapeutic approach having shown a survival gain in GC with PM. However, cytoreductive surgery (CRS) with peritonectomy procedures and intraperitoneal chemotherapy (IPC) promising new combined therapeutic approach to achieve disease control for GC with PM. The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival (OS). This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.
晚期胃癌（GC）发生腹膜转移（PM）时被认为是致命的疾病。对于晚期 GC 合并 PM，目前尚无标准治疗方法。直到 20 世纪 80 年代，这些患者的治疗领域仍然停滞不前，没有任何治疗方法在 GC 合并 PM 中显示出生存获益。然而，细胞减灭术（CRS）联合腹膜切除术和腹腔内化疗（IPC）为 GC 合并 PM 提供了一种有前途的新联合治疗方法，以实现疾病控制。最近的出版物通过提供 CRS 和 IPC 可延长整体生存（OS）的证据，改变了 GC 合并 PM 的治疗格局。本文将综述 CRS 和 IPC 在当前时代治疗晚期 GC 合并 PM 中的作用演变。
Zotero 插件